- <![CDATA[Dr McCann on the FDA Approval of Vepdegestrant for ESR1-Mutated, ER+ Advanced Breast Cancer]]><![CDATA[Kelly Elizabeth McCann, MD, PhD, notes the role of vepdegestrant in the ESR1-mutated, ER-positive, HER2-negative advanced breast cancer treatment paradigm.]]>onclive · 2mo ago↗ source
- <![CDATA[Honesty and Humor Provide Hope in Breast Cancer Survivorship: With Sara Nunnery, MD, MSCI; and Annie Bond]]><![CDATA[Dr Nunnery and Annie Bond discuss breast cancer survivorship and patient advocacy.]]>onclive · 2mo ago↗ source
- Lilly points to low-dose Zepbound and Foundayo as weight loss maintenance optionsReducing the dose of Eli Lilly’s obesity shot Zepbound could provide a safe, effective and potentially cheaper option for the maintenance of weight loss, according to new data. The findings come…